State of Wisconsin Investment Board
ELVN icon

State of Wisconsin Investment Board’s Enliven Therapeutics ELVN Stock Holding History

State of Wisconsin Investment Board’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
28,415
+8,017
+39% +$222K ﹤0.01% 1637
2025
Q4 		$314K Sell
20,398
-27,274
-57% -$543K ﹤0.01% 2150
2025
Q3 		$976K Sell
47,672
-9,110
-16% -$184K ﹤0.01% 1632
2025
Q2 		$1.14M Buy
56,782
+11,026
+24% +$209K ﹤0.01% 1526
2025
Q1 		$900K Buy
45,756
+18,921
+71% +$407K ﹤0.01% 1523
2024
Q4 		$604K Buy
26,835
+16,679
+164% +$432K ﹤0.01% 1724
2024
Q3 		$259K Sell
10,156
-10,134
-50% -$235K ﹤0.01% 2089
2024
Q2 		$474K Buy
20,290
+7,003
+53% +$147K ﹤0.01% 1851
2024
Q1 		$234K Sell
13,287
-4,954
-27% -$76K ﹤0.01% 2029
2023
Q4 		$252K Sell
18,241
-707
-4% -$8.65K ﹤0.01% 2117
2023
Q3 		$259K Sell
18,948
-3,234
-15% -$54.5K ﹤0.01% 2123
2023
Q2 		$453K Buy
+22,182
New +$448K ﹤0.01% 1858

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State of Wisconsin Investment Board's ELVN Position: Q1 2026 in Review

State of Wisconsin Investment Board increased its Enliven Therapeutics (ELVN) stake by 39% in Q1 2026, buying an estimated $222K and bringing the position to 28,415 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

State of Wisconsin Investment Board first reported a position in ELVN in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.14M in Q2 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • State of Wisconsin Investment Board held 28,415 shares of Enliven Therapeutics worth $1.11M as of Q1 2026.
  • State of Wisconsin Investment Board bought 8,017 Enliven Therapeutics shares in Q1 2026, an estimated $222K.
  • Enliven Therapeutics made up ﹤0.01% of State of Wisconsin Investment Board's portfolio in Q1 2026, its #1637 holding.
  • State of Wisconsin Investment Board first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • State of Wisconsin Investment Board's Enliven Therapeutics position peaked at $1.14M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on State of Wisconsin Investment Board's 13F filing for Q1 2026, filed 15 May 2026.